Study: NCT06137703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg non-enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg non-enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg non-enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg non-enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg immediate release tablet
Description: Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg immediate release tablet
Description: Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg immediate release tablet
Description: Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg immediate release tablet
Description: Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 2 x 100mg immediate release tablets
Description: 2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 2 x 100mg immediate release tablets
Description: 2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 2 x 100mg immediate release tablets
Description: 2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 2 x 100mg immediate release tablets
Description: 2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 4 x 25mg enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 4 x 25mg enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 4 x 25mg enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 4 x 25mg enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg